Sobi and Innate Pharma Collaborate to Advance Lacutamab for T-Cell Lymphoma Treatment

Strategic Partnership in Oncology: Sobi and Innate Pharma

Sobi® (Swedish Orphan Biovitrum AB) and Innate Pharma SA have announced an exciting strategic partnership aimed at advancing the development of lacutamab, an innovative treatment for cutaneous T-cell lymphoma (CTCL). This collaboration represents a pivotal step forward towards initiating the TELLOMAK-3 Phase 3 clinical trial, crucial for seeking accelerated approval for lacutamab specifically targeting Sézary syndrome, which is a rare and aggressive subtype of CTCL.

The TELLOMAK-3 Study

As part of the agreement, Innate Pharma will spearhead the TELLOMAK-3 confirmatory trial for lacutamab in CTCL patients. The intent of this study is to support an application for accelerated regulatory clearance in Sézary syndrome, followed by subsequent trials aimed at gaining full approval for both Sézary syndrome and the more common subtype, mycosis fungoides. This multi-phase approach underscores the commitment shared by both companies to improve treatment options and outcomes for patients suffering from this complex disease.

Exclusive Rights and Financial Terms

Upon receiving potential accelerated approval for lacutamab, Sobi will acquire exclusive global rights to commercialize the treatment. Furthermore, Sobi stands to gain full global development rights contingent upon successful outcomes from the Phase 3 trials. The partnership involves a transaction worth USD 75 million at closing, alongside performance-based milestones that could accrue additional funding, contingent upon the drug's advancement through the development phases and successful market entry.

Lacutamab: An Innovative Treatment Approach

Lacutamab is distinguished as a first-in-class anti-KIR3DL2 antibody, designed to tackle the challenges posed by cutaneous T-cell lymphomas, which comprise rare non-Hodgkin lymphomas including the severe Sézary syndrome. The development program for lacutamab has received multiple designations that highlight its potential: Fast Track from the FDA, PRIME from the EMA, and Orphan Drug status in both the U.S. and EU.

The TELLOMAK-3 study is set to be a randomized, open-label, multi-center trial that targets patients who have previously failed systemic therapies. The trial aims to deliver concrete results regarding efficacy and progression-free survival (PFS) rates, pivotal for obtaining full regulatory approval.

Expert Insights

Guido Oelkers, President and CEO of Sobi, expressed that this collaboration is essential for enhancing the company’s portfolio of rare disease therapies. He emphasizes the importance of aligning with a partner like Innate Pharma, which is deeply knowledgeable in clinical development for CTCL. Jonathan Dickinson, CEO of Innate Pharma, echoed enthusiasm about launching the TELLOMAK-3 trial, noting that Sobi’s extensive experience in rare diseases will be instrumental in unlocking lacutamab's full potential.

Conclusion

This partnership between Sobi and Innate Pharma exemplifies a powerful collaboration in the biopharmaceutical industry focused on addressing high unmet medical needs. By combining their resources, expertise, and commitment to innovation in oncology, both companies aim to expedite the availability of lacutamab to patients worldwide, ultimately improving the therapeutic landscape for T-cell lymphoma.

In summary, the journey of lacutamab reflects a broader vision to enhance treatment options and provide hope to patients battling rare forms of cancer. As development progresses, all eyes will be on the outcomes of the TELLOMAK-3 trial, potentially marking a new dawn in T-cell lymphoma therapies.